The clinical symptoms of a cohort of cystic fibrosis patients were related to their genotypes using RFLPs shown with MspI and the closely linked DNA marker MP6d-9. In the majority of CF chromosomes, the restriction site for MspI was present, and the genotype 2/2 was found most often in patients who were severely affected by the disease. The genotype 1/2 was significantly overrepresented in patients with very mild clinical manifestations, including pancreatic sufficiency, absence of meconium ileus, and absence of Pseudomonas colonisation. When pancreatic dysfunction was present, the 1/2 genotype was associated with a mild form, while the 2/2 genotype was found in
patients with severe insufficiency. None of our patients had the 1/1 genotype. These results indicate that the newly isolated MP6d-9 marker correlates with some important symptoms of cystic fibrosis.
Cystic fibrosis (CF) is an autosomal recessive disease with a prevalence of about 1 in 2000 live births and a carrier frequency ofapproximately 1 in 23 in Caucasian populations. 1 Linkage analysis has localised the CF mutation close to a protein variant,2 and then assigned it to the long arm of chromosome 7 using DNA markers.5 Several DNA probes tightly linked to the CF gene are currently in use for carrier detection and prenatal diagnosis in families with at least one affected child.69
The newly isolated marker, pMP6d-9 (D7S399), maps between the DNA sequences recognised by pKM19 (D7S23) and p13.11 (D7S8).10 pMP6d-9 is the closest, to date, to CF and is the one that shows the highest degree of non-random allelic association (linkage disequilibrium) in the Italian population."1
We report here a study on the correlation between the allelic systems determined by pMP6d-9, pXV2C, pKM.19, and pJ3. 11 The analysis of the relation between MP6d-9 genotypes and pancreatic dysfunction is shown in table 3. This table shows that there is a significant difference in the distribution of the MP6d-9 genotypes, with an overrepresentation of the 1/2 genotype in pancreatic sufficient, and of the 2/2 genotype in pancreatic insufficient patients. The mean ages of the patients included in the two groups were 8-7 years (insufficiency) and 14-6 years (sufficiency). All cases with pancreatic sufficiency had therefore reached an age at which the total or partial conservation of function allowed this group to be differentiated from the other. A similar analysis was performed with the pXV2C/TaqI, pKM19/PstI, and pJ3. 1 A further, more detailed analysis of the relation between the MP6d-9 genotype and the severity of pancreatic insufficiency is shown in table 4. When pancreatic insufficient patients were divided into two groups, according to the severity of the pancreatic dysfunction, it was found that the MP6d-9 1/2 genotype was overrepresented in the mild form, defined by <9 g/day steatorrhoea (without pancreatic enzyme supplementation), or by a steatocrit of <6%, or by a coefficient of fat absorption of >70%. This relation is highly significant for steatocrit, where the sample size is lowest, and almost significant (p=0087)-for steatorrhoea. Steatocrit has low specificity and high sensitivity and might depend, as well as steatorrhoea, on different dietary fat intake. Fat absorption, however, is independent of age, normalised for body weight, and calculated relative to known fat intake. Table 5 shows the relation between MP6d-9 genotypes and a division of CF into severe and mild clinical forms. Pancreatic insufficiency, meconium ileus, and Reudomonas colonisation were used as the major criteria to identify the two classes, the first including patients without any of the above manifestations, and the second including patients with one or more of them. The ages of the patients included in 
